Pharmacoeconomics of entecavir treatment for chronic hepatitis B

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 15, 2008, Pages 2673-2681

  You, Joyce H S ^a   Chan, Fredric W H ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic hepatitis B; Cost; Cost effectiveness; Entecavir; Pharmacoeconomics

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; FLU LIKE SYNDROME; HEALTH CARE COST; HEALTH ECONOMICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MEDLINE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SIDE EFFECT; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; ECONOMICS, PHARMACEUTICAL; GUANINE; HEPATITIS B, CHRONIC; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 55249097482     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.15.2673     Document Type: Review

References (50)

1. Lok AS, McMahon BJ. AASLD practice guidelines. Available from: http://www.aasld.org/eweb/docs/practiceguidelines/ chronichepBcorrection.pdf [Last accessed 2008 March 1]
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41
3. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211
4. Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006;66:1831-51
5. Hadziyannis SJ, Vassilopoulos D. Hepatits B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24
6. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91
7. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23
8. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13
9. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63
10. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8
11. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000;46:562-8
12. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55
13. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51
14. Papatheodoridis GV, Dimou E, Laras A, et al. Course of Virologsic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV Liver disease. Hepatology 2002;36:219-26
15. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6
16. Tassopoulos NC, Volpes R, Pastore G, et al. Efficiacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96
17. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:127-82
18. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
19. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
21. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81
22. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 KDa): and advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
23. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med 2005;352:2682-95
24. Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
25. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-54
26. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
27. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
28. Chang T, Gish R, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
29. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
30. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
31. Viread product package insert. August 2008
32. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of enteacivr versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007;25:963-77
33. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89
34. Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008;14:21-33
35. Yuan Y, Iloeje UH, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008;11(Suppl 1):S11-22
36. Kim WR, Veenstra DL, Iloeje UH, et al. The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion. Digestive Disease Week; 2005 May 14-19; Chicago, USA
37. Gish R, Chang T, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). American Association for the Study of Liver Diseases Annual Meeting; 2005 Nov 11-15; San Francisco, USA
38. Lee TA, Veenstra DL, Iloeje UH, et al Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004;38:S144-7
39. Levy AR, Gagnon YM, Hargreaves SJ, et al. Valuing health states using utility weights to capture the impact of disease progression in chronic hepatitis B. World Congress of Gastroenterology; 2005 Sept 9-14; Montreal, Canada
40. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65
41. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis c patients. Am J Gastroenterol 2003;98:630-8
42. Iloeje UH, Yang HI, Su J, et al. Risk evaluation of viral load elevation and associated liver disease/cancer in HBV (the REVEAL-HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
43. Chen CJ, Yan HI, Su J, et al. Risk of hepatacellular carcinoma across a biological gradient of serum hepatitis B Virus DNA level. JAMA 2006;295:65-73
44. Durand-Zaleski I, Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventing strategies. Med Decis Making 1994;12:98-103
45. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37
46. Lee TA, Veenstra D, Iloeje U, et al. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004;38(Suppl 3):S144-7
47. Levy AR, Kowdley KV, Iloeje UH, et al. The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons. Value Health 2008;11:527-38
48. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007;60:201-5
49. Zhiqiang G, Zhaohui Dong, Qinhuan Wang, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38:S175-8
50. WHO. Macroeconomics and health: investing in health for economic development-report of the commission on macroeconomics and health. Geneva, Switzerland: World Health Organization; 2001. Available from: www.who.int/choice/en